• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Amarin Corporation plc

    5/1/24 7:10:43 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRN alert in real time by email
    S-8 1 may_1_2024_s-8.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on May 1, 2024

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    AMARIN CORPORATION PLC

    (Exact name of registrant as specified in its charter)

    England and Wales

    Not Applicable

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

    Iconic Offices, The Greenway, Block C Ardilaun Court,

    112-114 St Stephens Green

    Dublin 2, Ireland

    +353 (0) 1 6699 020

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Amarin Corporation plc 2020 Stock Incentive Plan

    (Full title of the plans)

    Patrick Holt

    President and Chief Executive Officer

    Amarin Corporation plc

    c/o Amarin Pharma, Inc.

    440 Route 22

    Bridgewater, NJ 08807

    Telephone: (908) 719-1315

    (Name, address, and telephone number, including area code, of agent for service)

     


     

    Please send copies of all communications to:

    Jared Fertman, Esq.

    Willkie Farr & Gallagher LLP

    787 Seventh Avenue

    New York, NY 10019

    Telephone: (212) 728-8000

    Facsimile: (212) 728-8111

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☒

     

     

     

     

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☐

     

     

     

     

     

     

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐


     

     

     

    EXPLANATORY NOTE

    In February 2024, the Board of Directors of Amarin Corporation plc (the “Company”) approved, subject to shareholder approval, Amendment No. 3 to the Company’s 2020 Stock Incentive Plan (the “Plan”), which increased the aggregate number of the Company’s ordinary shares of £0.50 each or any American Depositary Shares (“ADSs”) (or equivalent security) as the case may be (“Shares”) authorized for issuance under the Plan by 10,000,000 Shares (the “Plan Amendment”). At the Company’s 2024 Annual General Meeting held on April 18, 2024 (the “2024 AGM”), the Company’s shareholders approved the Plan Amendment. The contents of the Company’s Registration Statement on Form S-8 (File No. 333-240321) filed with the Securities and Exchange Commission (the “Commission”) on August 4, 2020, the Company’s Registration Statement on Form S-8 (File No. 333-266611) filed with the Commission on August 5, 2022 and the Company’s Registration Statement on Form S-8 (File No. 333-273952) filed with the Commission on August 2, 2023, each relating to the Plan, are incorporated by reference into this Registration Statement pursuant to General Instruction E to Form S-8. This Registration Statement registers, among other securities described below, (a) the 10,000,000 Shares reserved for issuance under the Plan pursuant to the Plan Amendment and (b) 6,927,178 Shares underlying awards that expired, were forfeited, surrendered, canceled or otherwise terminated in whole or in part, other than through exercise, under the Company’s 2011 Stock Incentive Plan (as amended, the “2011 Plan”) subsequent to July 21, 2023, which may be made available for grants under the Plan (pursuant to the Plan) at the discretion of the Remuneration Committee of the Amarin Board of Directors.

    Part I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1. Plan Information.

    The documents containing the information specified in this Item 1 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act of 1933 (the “Securities Act”). In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

    Item 2. Registrant Information and Employee Plan Annual Information.

    The documents containing the information specified in this Item 2 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.


     

     

     

    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    Amarin Corporation plc (the “Company”) hereby incorporates by reference in this Registration Statement the following documents previously filed by the Company with the Commission:

    1.
    The Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (other than information furnished rather than filed);
    2.
    The Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2024;
    3.
    The Company’s Current Reports on Form 8-K filed with the Commission on January 26, 2024, April 3, 2024 and April 22, 2024; and
    4.
    The description of the Shares contained in the “Description of Registrant’s Securities” filed as Exhibit 4.4 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

    All documents that the Company subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act” ) prior to the filing of a post-effective amendment to this registration statement which indicates that all of the ordinary shares offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be a part hereof from the date of the filing of such documents.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

    Under no circumstances will any information furnished under Items 2.02 or 7.01 of a Current Report on Form 8-K (including those referenced above) be deemed incorporated herein by reference, unless such Form 8-K expressly provides to the contrary.


     

     

     

    Item 8. Exhibits.

    Exhibit
    No.

    Description of Exhibit

     

     

    4.1

    Articles of Association of Amarin Corporation plc (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the Commission on April 22, 2024, File No. 000-21392).

     

     

    4.2

    Amarin Corporation plc 2020 Stock Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the Commission on July 14, 2020, File No. 000-21392).

     

     

    4.3

    Amendment No. 1 to the Amarin Corporation plc 2020 Stock Incentive Plan (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the Commission on June 30, 2022, File No. 000-21392).

     

     

    4.4

    Amendment No. 2 to the Amarin Corporation plc 2020 Stock Incentive Plan (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the Commission on July 25, 2023, File No. 000-21392).

     

     

     

    4.5

     

    Amendment No. 3 to the Amarin Corporation plc 2020 Stock Incentive Plan (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the Commission on April 22, 2024, File No. 000-21392).

     

     

    4.6

    Form of Ordinary Share certificate (incorporated herein by reference to Exhibit 2.4 to the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2002, filed with the Commission on April 24, 2003).

     

     

    4.7

    Form of American Depositary Receipt evidencing ADSs (incorporated herein by reference to Exhibit 4.4 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011, filed with the Commission on February 29, 2012).

     

     

    *5.1

    Opinion of K&L Gates LLP.

     

     

    *23.1

    Consent of Ernst & Young LLP, independent registered public accounting firm.

     

     

    *23.2

    Consent of K&L Gates LLP (included in Exhibit 5.1).

     

     

    *24.1

    Power of Attorney (included in the Registration Statement under “Signatures”).

     

     

    *107

    Filing Fee Table

     

    *

    Filed herewith.

     


     

     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the city of Dublin Ireland, on May 1, 2024.

     

    Amarin Corporation plc

     

     

    By:

    /s/ Patrick Holt

     

    Patrick Holt, President and Chief Executive Officer

    SIGNATURES AND POWER OF ATTORNEY

    We, the undersigned officers and Directors of Amarin Corporation plc, hereby severally constitute and appoint Patrick Holt and Tom Reilly, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and stead, and in any and all capacities, to sign for us and in our names in the capacities indicated below any and all amendments (including post-effective amendments) to this registration statement on Form S-8 (or any other registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.


     

    Signature

    Title

    Date

     

     

     

    /s/ Patrick Holt

    Director, President and Chief Executive

    May 1, 2024

    Patrick Holt

    Officer (Principal Executive Officer)

     

     

     

     

    /s/ Tom Reilly

    Chief Financial Officer

    May 1, 2024

    Tom Reilly

    (Principal Financial and Accounting Officer)

     

     

     

     

    /s/ Patrice Bonfiglio

    Director

    May 1, 2024

    Patrice Bonfiglio

     

     

     

     

     

    /s/ Paul Cohen

    Director

    May 1, 2024

    Paul Cohen

     

     

     

     

     

    /s/ Mark DiPaolo

    Director

    May 1, 2024

    Mark DiPaolo

     

     

     

     

     

    /s/ Keith L. Horn

    Director

    May 1, 2024

    Keith L. Horn

     

     

     

     

     

    /s/ Odysseas Kostas

    Director

    May 1, 2024

    Odysseas Kostas

     

     

     

     

     

    /s/ Oliver O’Connor

    Director

    May 1, 2024

    Oliver O’Connor

     

     

     

     

     

    /s/ Louis Sterling III

    Director

    May 1, 2024

    Louis Sterling III

     

     

     

     

     

    /s/ Diane E. Sullivan

    Director

    May 1, 2024

    Diane E. Sullivan

     

     


    Get the next $AMRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMRN

    DatePrice TargetRatingAnalyst
    11/20/2023Underweight
    JP Morgan
    10/25/2023$3.00 → $1.00Buy → Hold
    Jefferies
    1/6/2023$1.30 → $3.00Hold → Buy
    Jefferies
    5/6/2022Neutral → Underweight
    JP Morgan
    5/5/2022$10.00 → $3.00Outperform → Mkt Perform
    SVB Leerink
    5/5/2022$10.00 → $3.00Buy → Neutral
    H.C. Wainwright
    5/4/2022Outperform → Market Perform
    Northland Capital
    2/16/2022$11.00 → $10.00Outperform
    SVB Leerink
    More analyst ratings

    $AMRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026

    DUBLIN and BRIDGEWATER, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report fourth quarter and full year 2025 financial results and conduct a conference call on Wednesday, February 25, 2026. The Company will issue a press release detailing its fourth quarter and full year 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call:Via telephone: Dial in within the United States: 888-506-0062International dial in: 973-528-0011Acces

    2/11/26 8:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

    DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on recent innovations in therapies for patients with elevated triglycerides (TG) and shared its perspective on how these developments stand to shape patient access and treatment strategies. Specifically, new therapies for these patients are likely to expand the use of existing, proven options over time, including Amarin's VASCEPA®/VAZKEPA® (icosapent ethyl), an effective, safe, oral therapy that has been prescribed more than 25 million times to patients globally. In addition, through its approved indi

    1/9/26 7:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities

    DUBLIN and BRIDGEWATER, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced select preliminary unaudited 2025 financial highlights, provided a summary of key 2025 operational accomplishments, and outlined 2026 priorities in advance of business development and investor meetings in San Francisco during the week of January 12, 2026. Creating a New Operating Paradigm from a Position of Strength"Our preliminary results for the fourth quarter and full year 2025 represent an inflection point in the evolution of Amarin," said Aaron Berg, Chief Executive Officer. "We are executing o

    1/8/26 7:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Berg Aaron converted options into 4,179 units of American Depositary Shares and covered exercise/tax liability with 2,298 units of American Depositary Shares, increasing direct ownership by 2% to 82,595 units (SEC Form 4)

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    2/3/26 7:00:09 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, Chief Legal Officer Provoost Jonathan

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    2/3/26 7:00:07 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Scientific Officer Ketchum Steven B converted options into 4,179 units of American Depositary Shares and covered exercise/tax liability with 2,297 units of American Depositary Shares, increasing direct ownership by 5% to 40,879 units (SEC Form 4)

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    2/3/26 7:00:05 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Berg Aaron bought $102,400 worth of Ordinary Shares (160,000 units at $0.64), increasing direct ownership by 25% to 805,380 units (SEC Form 4)

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    8/5/24 5:30:03 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Holt Patrick bought $15,724 worth of Ordinary Shares (14,426 units at $1.09), increasing direct ownership by 5% to 314,426 units (SEC Form 4)

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    1/24/24 4:31:21 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JP Morgan resumed coverage on Amarin

    JP Morgan resumed coverage of Amarin with a rating of Underweight

    11/20/23 7:16:51 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin downgraded by Jefferies with a new price target

    Jefferies downgraded Amarin from Buy to Hold and set a new price target of $1.00 from $3.00 previously

    10/25/23 6:25:52 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin upgraded by Jefferies with a new price target

    Jefferies upgraded Amarin from Hold to Buy and set a new price target of $3.00 from $1.30 previously

    1/6/23 7:26:32 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    SEC Filings

    View All

    Amarin Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

    1/8/26 7:05:27 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Amarin Corporation plc

    10-Q - AMARIN CORP PLC\UK (0000897448) (Filer)

    10/29/25 7:05:49 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

    10/29/25 7:05:27 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Leadership Updates

    Live Leadership Updates

    View All

    Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

    DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member of the Board of Directors, effective immediately. "On behalf of the board, I welcome Michael. His financial expertise, experience on other boards and, as a fellow shareholder, his shared priority to continue focusing on strategies to maximize shareholder value, make him a beneficial addition to the board at this time," said Odysseas Kostas, MD, Chairman of the Board. "I am eager to join the board and begin working with fellow directors and the s

    4/7/25 7:30:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Appoints Peter Fishman Chief Financial Officer

    DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Peter Fishman has been appointed as Chief Financial Officer for the Company, effective immediately. He will be responsible for leading Amarin's global finance organization and will report directly to the Company's Chief Executive Officer, Aaron Berg. Most recently, Mr. Fishman served as the Company's Global Controller and principal financial and accounting officer. "Pete brings tremendous experience to his new role at Amarin, including most recently as a trusted advisor to our leadership team serving as principal financial and accounting officer for the Company," said

    12/13/24 9:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Board of Directors Announces CEO Transition

    -- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as President & CEO of the Company. "On behalf of the Company's Board of Directors, I thank Pat for his contributions to Amarin, and I welcome working closely again with Aaron

    6/4/24 7:30:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Financials

    Live finance-specific insights

    View All

    Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026

    DUBLIN and BRIDGEWATER, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report fourth quarter and full year 2025 financial results and conduct a conference call on Wednesday, February 25, 2026. The Company will issue a press release detailing its fourth quarter and full year 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call:Via telephone: Dial in within the United States: 888-506-0062International dial in: 973-528-0011Acces

    2/11/26 8:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Reports Third Quarter 2025 Financial Results

    Company completes transition to fully partnered commercialization model across all international markets Q3 2025 performance reflects initial impact of new approach to Europe, ongoing expansion of Rest-of-World demand, continued success in managing US market, and initial operating margin improvements following corporate rightsizingTargeting sustainable positive free cash flow in 2026 DUBLIN and BRIDGEWATER, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today announced financial results for the third quarter of 2025. "With the reporting of Q3 2025 we usher in the next phase i

    10/29/25 7:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025

    DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report third quarter 2025 financial results and conduct a conference call on Wednesday, October 29, 2025. The Company will issue a press release detailing its third quarter 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call: Via telephone: Dial in within the United States: 877-545-0523 International dial in: 973-528-0016 Access Code: 459510  V

    10/15/25 8:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Amarin Corporation plc (Amendment)

    SC 13G/A - AMARIN CORP PLC\UK (0000897448) (Subject)

    12/8/23 4:26:23 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Amarin Corporation plc (Amendment)

    SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

    12/5/23 7:30:10 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Amarin Corporation plc (Amendment)

    SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

    9/5/23 4:15:30 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care